I'll research JNJ's recent performance, guidance, and key issues before writing the preview. Let me start by gathering recent materials.I have the Q1 2026 release. Let me get the earnings call transcript and recent news to understand key debates going into Q2.Let me gather recent news context and stock performance to round out the preview.I now have what I need. Here's the earnings preview.
JNJ enters this print with real momentum — arguably the strongest sentiment it has enjoyed in years. The stock has climbed from roughly $207 at the start of January to ~$254 today, up ~22% YTD, hitting an intraday-basis high around $267 on July 7 before a modest pullback into the print. That run has been fueled by clean pipeline execution, de-risked launches, and a narrative shift toward JNJ as "the cleanest growth story in healthcare." The flip side: the bar is higher now than it has been in a long time, and a simple in-line quarter may not be enough to satisfy a stock trading near all-time highs.
Consensus for Q2 (per the latest sell-side digest): | Metric | Consensus | |---|---| | Adjusted EPS | $2.86 | | Total revenue | ~$25.0B (+5.4% y/y) | | Innovative Medicine | ~$16.1B (+6%) | | MedTech | ~$8.9B (+5.25%) |
Sentiment heading in is bullish, anchored on portfolio reshuffling, execution, and positive drug-data readouts.
| Metric (FY2026, April guide) | Range | Midpoint / Growth |
|---|---|---|
| Reported sales | $100.3–101.3B | $100.8B / +7.0% |
| Operational sales | $99.7–100.7B | $100.2B / +6.4% |
| Adj. operational sales growth | — | +5.6%–6.6% / +6.1% |
| Adjusted EPS | $11.45–11.65 | $11.55 / +7.1% |
| Adj. operational EPS | $11.30–11.50 | $11.40 / +5.7% |
| Adj. pre-tax operating margin | ≥ +50 bps improvement | — |
| Free cash flow | ~$21B | — |
Key phasing points for your model: management guided to fairly consistent operational growth with a higher Q4 (the 2026 calendar has a 53rd week worth ~100 bps, weighted to Q4); first-half is the heavy investment/margin-pressure period, so Q2 margins may again look soft; and there's a known 2H China VBP headwind in electrophysiology. Given the Q1 raise and strong momentum, the debate is whether management raises again — and if so, whether it's just the FX/beat flow-through or a genuine underlying step-up.
STELARA fell ~62% in Q1 and is the single biggest drag on reported growth. The bull case ("ex-STELARA double digits") only works if the base business keeps outrunning it. Watch the magnitude and trajectory of the STELARA headwind — evidence that it's stabilizing/annualizing would de-risk the acceleration story into 2027.
Q1 standouts to watch again: DARZALEX (+18%, now a ~$4B/qtr, #1 product), TREMFYA (+64%), CARVYKTI (+57%), TECVAYLI (+30%), TALVEY (+73%), RYBREVANT+LAZCLUZE (+80%), ERLEADA (+16%), SPRAVATO (+45%). TREMFYA's IBD ramp and continued IL-23 share gains are central to the multi-year thesis.
Management explicitly argues these are underappreciated: - ICOTYDE (icotrokinra) — the first oral IL-23 peptide for plaque psoriasis, flagged as "potentially one of JNJ's largest products ever." Q2 is the first full quarter of launch data. Watch: script trajectory (was ~1,500 patients / ~1,000 prescribers early), payer/access breadth (permanent J-code effective April 1), source of business (topical switchers vs. biologic switchers vs. new), and the ICONIC-ASCEND head-to-head data vs. TYK2. - INLEXZO (non-muscle-invasive bladder cancer) — post-J-code inflection; management cited +50%→+90% week-over-week jumps in new insertions in early April. Watch whether that sustains. - CAPLYTA (Intra-Cellular) — adjunctive MDD launch; >$5B peak sales ambition; bipolar mania data due later this year.
Device sentiment is soft industry-wide, so the read-through matters. Q1 cardio was strong (Abiomed +14%, Shockwave +18%, EP +9.5%/VARIPULSE). Watch for: IVL competitive entrants vs. Shockwave, the China VBP hit to EP in 2H, U.S. surgical-vision competitive pressure (U.S. surgical vision declined ~3% in Q1), TECNIS PureSee U.S. launch, and progress on the OTTAVA surgical robot. MedTech margins carry the most tariff exposure.
The Q1 EPS decline was the one blemish. With heavy 1H investment and tariff drag flagged, Q2 margin/EPS quality will be scrutinized — investors want confidence in the "≥50 bps margin improvement" full-year commitment and a 2H recovery.
JNJ is targeting a mid-2027 separation of DePuy Synthes and is "evaluating all separation vehicles." Any update on structure/timing is a catalyst — the separation is part of the argument for structurally higher go-forward growth.
JNJ raised the dividend 3.1% to $5.36/share (64th consecutive annual increase). The bigger event is the Enterprise Business Review on December 8, 2026, where management will lay out its path to double-digit growth by end of decade — a story further helped when U.S. DARZALEX royalties roll off in 2029. This quarter's job is to keep that credibility intact.
This is a "prove the acceleration" quarter. Consensus (~$2.86 EPS, ~$25.0B revenue) embeds continued base-business strength offsetting STELARA. The bull case rests on (a) ex-STELARA double-digit growth persisting, (b) early ICOTYDE/INLEXZO traction validating the "underappreciated launches" thesis, and (c) a guidance raise. The risks are a soft-EPS/margin quarter amplified by tariffs and 1H investment, any deceleration in MedTech, and litigation headlines (Tylenol just resurfaced). With the stock near record highs and up ~22% YTD, expectations leave little room for disappointment — the reaction will hinge as much on the guidance revision and launch commentary as on the headline beat.
Watch list on the print: (1) size of STELARA drag, (2) ICOTYDE script/access metrics, (3) MedTech organic growth ex-China-VBP and margins, (4) any guidance raise vs. just FX, (5) ortho separation and litigation commentary.
Note: Figures above are drawn from JNJ's Q1 2026 earnings release and call, the pre-earnings sell-side consensus digest, recent news, and market pricing. Adjusted (non-GAAP) figures are used where noted; guidance excludes unquantifiable GAAP items such as litigation.